RATIONALE: Gathering information about how often metabolic syndrome occurs in young survivors of childhood leukemia who have undergone stem cell transplant may help doctors learn more about the disease and the long-term effects of leukemia treatment. It may also help improve the quality of life for future cancer survivors. PURPOSE: This clinical trial is studying metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone stem cell transplant.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Comparison of the prevalence of metabolic syndrome in adolescent and young adult survivors of childhood leukemia who have undergone hematopoietic stem cell transplantation (HSCT) with age- and gender-matched controls
Timeframe: ≥2 years post-HSCT
Comparison of insulin resistance in patients with age- and gender-matched controls
Timeframe: ≥2 years post-HSCT
Correlation between insulin sensitivity and risk factors associated with metabolic syndrome
Timeframe: ≥2 years post-HSCT
Influence of time since transplant on insulin resistance
Timeframe: ≥2 years post-HSCT
Peak growth hormone secretion in patients with insulin resistance and in those without
Timeframe: ≥2 years post-HSCT
Growth hormone deficiency in patients with metabolic syndrome and in those without
Timeframe: ≥2 years post-HSCT
Association of interleukin-6, tumor necrosis factor-α, C-reactive protein, and leptin with insulin resistance and central obesity
Timeframe: ≥2 years post-HSCT
Correlation of adiponectin with insulin resistance and central obesity
Timeframe: ≥2 years post-HSCT
Differences in markers for endothelium dysfunction and early indicators of cardiovascular disease
Timeframe: ≥2 years post-HSCT
Difference in important health behaviors related to obesity and cardiovascular disease between patients with metabolic syndrome and those without
Timeframe: ≥2 years post-HSCT